Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma

Table 5 Risk factors for hepatocellular carcinoma recurrence post-liver transplant (Logistic regression analysis)

Variable	No HCC recurrence/HCC recurrence(n = 62/6)	Univariate OR(95%CI)	P value	Multivariate OR (95%CI)	P value
Age > 60 yr	39/3	0.6 (0.1-4.8)	0.8
Male	45/5	1.9 (0.2-94.5)	0.9
White	34/3	0.8 (0.1-6.7)	0.9
Baseline BMI(≥ 25 kg/m2)	50/4	0.5 (0.1-5.9)	0.7
EOT BMI (< 25 kg/m2)	11/4	8.8 (1.1-109.3)	0.03	12.3 (1.2-131.0)	0.03
Alcohol drinking	28/4	2.4 (0.3-28.3)	0.6
Cigarette smoking	48/3	0.3 (0.1-2.5)	0.3
Cirrhosis	4/0	-	-
Pre-LT relapse to DAA	18/5	11.7 (1.2-590.7)	0.006	14.9 (1.1-219.3)	0.04
Anti-HBc-positive allograft	8/2	3.3 (0.3-27.8)	0.4
HCV-positive allograft	4/0	-	-
HCV genotype 3a	12/3	4.1 (0.5-34.2)	0.2
Post-LT relapse to DAA	2/3	26.2 (2.2-432.9)	0.002	10.6 (1.0-121.6)	0.05

HCC: Hepatocellular carcinoma; BMI: Body mass index; DAA: Direct-acting antiviral; HCV: Hepatitis C virus; OR: Odds ratio; CI: Confidence interval; LT: Liver transplant; HBc: Hepatitis B core; EOT: End of treatment.